8-K
filed August 2, 2022, 7:59 PM ET
ticker HIND
CIK 0001427570
leadership
confidence high
sentiment neutral
materiality 0.65
ReShape Lifesciences appoints Paul F. Hickey as CEO, effective Aug 15, 2022
Vyome Holdings, Inc
- Paul F. Hickey appointed President and CEO, succeeds Bart Bandy who departed to pursue other opportunities.
- CFO Thomas Stankovich serves as interim CEO until Hickey joins; Dan Gladney becomes Executive Chair.
- Hickey receives $400K base salary, bonus up to 50% of salary, and stock option grant of 4% fully diluted shares.
- Stankovich receives retention bonus of 100% target 2022 cash bonus if employed through Dec 31, 2022.
- Hickey previously SVP Marketing at EnteroMedics (predecessor ReShape) and CEO at Altimate Medical.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Bart Bandy resigned as Member of the Board of Directors at Vyome Holdings, Inc.
- Action
- resigned
- Role
- Member of the Board of Directors
Exact text from the filing
Mr. Bandy also resigned from the Board of Directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paul F. Hickey was appointed as Member of the Board of Directors at Vyome Holdings, Inc.
- Action
- appointed
- Role
- Member of the Board of Directors
Exact text from the filing
On July 27, 2022, ReShape Lifesciences Inc. (the “Company”) announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as a member of the Board of Directors, effective August 15, 2022.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Bart Bandy departed as President and Chief Executive Officer at Vyome Holdings, Inc.
- Action
- separated
- Role
- President and Chief Executive Officer
Exact text from the filing
Mr. Hickey succeeds Bart Bandy, who has separated from the Company to pursue other opportunities.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paul F. Hickey was appointed as President and Chief Executive Officer at Vyome Holdings, Inc.
- Action
- appointed
- Role
- President and Chief Executive Officer
Exact text from the filing
On July 27, 2022, ReShape Lifesciences Inc. (the “Company”) announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as a member of the Board of Directors, effective August 15, 2022.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Thomas Stankovich was appointed as Interim President and Chief Executive Officer at Vyome Holdings, Inc.
- Action
- appointed
- Role
- Interim President and Chief Executive Officer
Exact text from the filing
Thomas Stankovich, Chief Financial Officer of the Company, will serve as Interim President and Chief Executive Officer until Mr. Hickey joins the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dan W. Gladney was appointed as Executive Chair at Vyome Holdings, Inc.
- Action
- appointed
- Role
- Executive Chair
Exact text from the filing
Dan W. Gladney, current Chair of the Board of Directors, will assume a more active role as Executive Chair, supporting Mr. Hickey and the Company on strategic matters
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.